Deerland Probiotics & Enzymes announced that the United States Patent and Trademark Office has published its application for a distinct use of Deerland’s signature strain DE111® of the probiotic species, Bacillus subtilis DE111® based on compelling human clinicals performed on DE111®.
The patent application (US# 2021-315808 A1) titled “Bacillus subtilis containing composition for treatment of gastrointestinal irregularity” claims the use of B. subtilis strain DE111® for promoting GI and bowel regularity. Deerland envisions additional applications for supplements and functional foods/beverages claiming anti-fungal and anti-microbial properties that exert health benefits of gastrointestinal regularity, immune support and balancing of the microbiome.